GlassScriptPhysician profile
Nalin K Srivastava
NPI 1023065828
$15,333.84
in general payments reported to CMS, 2019-2025
41 companies · $5,912 in 2025
The $5,912 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,360 · 2020: $1,022 · 2021: $916 · 2022: $1,449 · 2023: $1,559 · 2024: $3,115 · 2025: $5,912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,212 · Travel and Lodging: $4,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,211.52 |
| Travel and Lodging | $4,374.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $3,101.32 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Medtronic, INC. | $3,099.83 | 2021-2025 | Corevalve Evolut R, Onyx Frontier, Hawkone |
| Abbott Laboratories | $2,648.86 | 2019-2025 | Optis, Xience Sierra, Pressurewire |
| Abiomed | $856.45 | 2020-2025 | Impella |
| Boston Scientific Corporation | $826.08 | 2019-2025 | Watchman Access System, Watchman Flx, Rotapro |
| Biotronik INC. | $688.25 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $616.58 | 2019-2025 | |
| Inari Medical, INC. | $542.45 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $297.88 | 2022-2025 | Camzyos, Eliquis |
| Stryker Corporation | $288.22 | 2025 | Flowtriever, Clottriever Bold Catheter, Venacore Thrombectomy Catheter |
| Atricure, INC. | $282.92 | 2022-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Astrazeneca Pharmaceuticals LP | $253.75 | 2019-2023 | |
| Pfizer INC. | $164.55 | 2022-2025 | |
| Cvrx, INC. | $151.30 | 2023-2025 | Barostim Neo System |
| Medtronic Vascular, INC. | $150.28 | 2019 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $137.17 | 2020-2023 | Xarelto |
| Heartflow, INC. | $126.58 | 2025 | |
| Asahi Intecc USA, INC. | $120.56 | 2025 | Asahi Interventional Radiology Wires |
| Cardiva Medical, INC. | $110.22 | 2022-2025 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Vvcs 6-12f |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.69 | 2019-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $96.01 | 2021-2022 | |
| Chiesi USA, INC. | $88.47 | 2019-2025 | Kengreal |
| Cardiovascular Systems INC. | $73.86 | 2019-2020 | |
| Angiodynamics, INC. | $52.93 | 2025 | Angiovac |
| Amgen INC. | $50.60 | 2021-2024 | Repatha |
| Intuitive Surgical, INC. | $48.73 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $39.61 | 2023 | Arcalyst |
| Cms Imaging, INC. | $39.06 | 2025 | |
| Philips North America LLC | $38.96 | 2023-2024 | (Br0) Coronary Atherectomy |
| Kestra Medical Technology Services, INC. | $32.30 | 2023-2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $29.34 | 2025 | Onpattro |
| Recor Medical INC | $24.93 | 2024 | Paradise Renal Denervation System |
| Shockwave Medical, INC | $23.72 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.54 | 2021 | |
| Teleflex LLC | $18.52 | 2024 | Guideliner |
| Amarin Pharma, INC. | $16.83 | 2019 | |
| W. L. Gore & Associates, INC. | $16.03 | 2025 | Gore Cardioform Septal Occluder |
| Cagent Vascular INC | $15.30 | 2025 | Serrantor |
| Cardinal Health 200 LLC | $14.66 | 2019 | |
| Nuwellis, INC. | $13.82 | 2019 | |
| Surmodics, INC. | $13.68 | 2023 | Pounce Thrombectomy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalin Srivastava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.